Cardiol Therapeutics (CRDL) Expected to Announce Earnings on Tuesday

Cardiol Therapeutics (NASDAQ:CRDL) is expected to be posting its Q4 2025 results after the market closes on Tuesday, March 31st. Analysts expect Cardiol Therapeutics to post earnings of ($0.09) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, April 10, 2026 at 4:00 PM ET.

Cardiol Therapeutics Stock Performance

CRDL opened at $1.25 on Monday. The stock’s fifty day moving average is $1.02 and its two-hundred day moving average is $1.04. The company has a market capitalization of $139.68 million, a P/E ratio of -4.17 and a beta of 1.02. Cardiol Therapeutics has a 52 week low of $0.77 and a 52 week high of $1.59. The company has a quick ratio of 3.89, a current ratio of 3.89 and a debt-to-equity ratio of 0.01.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CRDL. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Cardiol Therapeutics in a research report on Tuesday, February 10th. upgraded Cardiol Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cardiol Therapeutics has an average rating of “Hold” and a consensus price target of $9.00.

Hedge Funds Weigh In On Cardiol Therapeutics

Several institutional investors have recently bought and sold shares of the business. Bank of America Corp DE raised its stake in Cardiol Therapeutics by 1,983.0% in the third quarter. Bank of America Corp DE now owns 551,053 shares of the company’s stock worth $590,000 after buying an additional 524,598 shares in the last quarter. Citadel Advisors LLC boosted its position in Cardiol Therapeutics by 1,132.6% during the 3rd quarter. Citadel Advisors LLC now owns 463,462 shares of the company’s stock valued at $496,000 after acquiring an additional 425,862 shares in the last quarter. Two Sigma Investments LP purchased a new position in shares of Cardiol Therapeutics in the 3rd quarter valued at $249,000. Virtu Financial LLC purchased a new position in shares of Cardiol Therapeutics in the 3rd quarter valued at $154,000. Finally, Susquehanna International Group LLP raised its position in shares of Cardiol Therapeutics by 366.5% in the 3rd quarter. Susquehanna International Group LLP now owns 93,398 shares of the company’s stock worth $100,000 after acquiring an additional 73,375 shares in the last quarter. 12.49% of the stock is owned by hedge funds and other institutional investors.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) is a clinical-stage pharmaceutical company dedicated to developing immunomodulatory treatments for patients with cardiovascular disease. The company’s lead asset, CardiolRx, is a proprietary, pharmaceutical-grade cannabidiol (CBD) formulation designed to target the inflammation and oxidative stress underlying conditions such as acute myocardial injury and heart failure. Cardiol holds exclusive global rights to CardiolRx through a licensing partnership and is advancing additional preclinical programs focused on small-molecule immunotherapies for heart disease.

CardiolRx is formulated for oral administration and has been evaluated in a randomized, placebo-controlled Phase 2 myocardial protection study assessing safety and key biomarkers following acute coronary syndromes.